GP
TEVA icon

Girard Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Girard Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,943
Closed -$41K – 762
2018
Q3 		$41K Buy
+1,943
New +$45.1K 0.01% 484
2016
Q3 		– Sell
-4,080
Closed -$205K – 209
2016
Q2 		$205K Sell
4,080
-2,020
-33% -$108K 0.08% 184
2016
Q1 		$326K Buy
6,100
+822
+16% +$48.2K 0.14% 141
2015
Q4 		$346K Buy
5,278
+1,490
+39% +$92.1K 0.17% 131
2015
Q3 		$214K Sell
3,788
-849
-18% -$55K 0.12% 147
2015
Q2 		$274K Buy
4,637
+851
+22% +$52.5K 0.15% 130
2015
Q1 		$236K Buy
3,786
+1
+0% +$58 0.14% 129
2014
Q4 		$218K Buy
+3,785
New +$211K 0.14% 133

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Girard Partners's TEVA Position: Q4 2018 in Review

Girard Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 1,943 shares — an estimated $41K sold.

Girard Partners first reported a position in TEVA in Q4 2014 and held it in 8 quarters. The position peaked at $346K in Q4 2015. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Girard Partners reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Girard Partners sold 1,943 Teva Pharmaceuticals shares in Q4 2018, an estimated $41K.
  • Girard Partners first reported a position in Teva Pharmaceuticals in Q4 2014 and held it in 8 quarters.
  • Girard Partners's Teva Pharmaceuticals position peaked at $346K in Q4 2015.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.